Impact of prior infection status on antibody response to the BNT162b2 mRNA COVID-19 vaccine in healthcare workers at a COVID-19 referral hospital in Milan, Italy

• Egile Nagusiak: Laura Milazzo (Egilea), Laura Pezzati (Egilea), Letizia Oreni (Egilea), Cristina Kullmann (Egilea), Alessia Lai (Egilea), Arianna Gabrieli (Egilea), Giovanna Bestetti (Egilea), Cristian Beschi (Egilea), Federico Conti (Egilea), Cosimo Ottomano (Egilea), Cristina Gervasoni (Egilea), Luca Meroni (Egilea), Massimo Galli (Egilea), Spinello Antinori (Egilea), Anna Lisa Ridolfo (Egilea)
• Formatua: Liburua
• Argitaratua: Taylor & Francis Group, 2021-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

In Italy, SARS-CoV-2 vaccination campaign prioritized healthcare workers (HCWs) to receive two doses of BNT162b2 vaccine, irrespective of a previous SARS-CoV-2 infection. In this real-life study, we compared the humoral response to BNT162b2 vaccine in HCWs with and without a previous SARS-CoV-2 infe...